Digital Content 
NEWS #PharmaBuzz
22 Apr 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/04/22/3278820/0/en/nrx-pharmaceuticals-reports-positive-fda-office-of-generic-drugs-feedback-on-preservative-free-ketamine-program.html
06 Apr 2026
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/alar-breaks-key-barriers-in-ketamine-therapy-with-positive-phase-1-results-for-long-acting-injectable-ala-3000-for-treatment-resistant-depression-302734540.html
17 Mar 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/03/17/3257011/0/en/NRx-Pharmaceuticals-Nasdaq-NRXP-Announces-FDA-Bioequivalence-Determination-by-Office-of-Generic-Drugs-for-NRx-s-Preservative-Free-Ketamine-Application.html
16 Mar 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/03/16/3256130/0/en/NRx-Pharmaceuticals-Nasdaq-NRXP-Confirms-Path-to-New-Drug-Application-with-Real-World-Data-and-Broader-Proposed-Indication-for-NRX-100-ketamine-Following-Type-C-FDA-Meeting.html
18 Feb 2026
// FDA
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-february-18-2026-14056.pdf
14 Jan 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/01/14/3218507/0/en/NRx-Pharmaceuticals-Nasdaq-NRXP-Announces-70-000-Patient-Data-on-Real-World-Use-of-Ketamine-for-Treatment-of-Suicidal-Depression-to-be-Submitted-to-the-FDA-in-Support-of-NRX-100-Ap.html
Share